About Us

Arcturus Therapeutics a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1244fxF_230.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_external_thumbnail.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/18arct1055fxF_230.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1637797854
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg?time=1637797854

News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
READ MORE
June 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 26, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
READ MORE
July 28, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
READ MORE
August 2, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
August 3, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
READ MORE
August 9, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
READ MORE
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
September 8, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
READ MORE
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
READ MORE
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
READ MORE
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
READ MORE
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
READ MORE